scholarly journals CD4+ T cell responses in human viral infection: lessons from hepatitis C

2020 ◽  
Vol 130 (2) ◽  
pp. 595-597
Author(s):  
Benedikt Binder ◽  
Robert Thimme
Hepatology ◽  
2003 ◽  
Vol 38 ◽  
pp. 436-436
Author(s):  
H HOLZMANN ◽  
J ABERLE ◽  
P STEINDLMUNDA ◽  
E FORMAN ◽  
W JESSNER ◽  
...  

2012 ◽  
Vol 19 (12) ◽  
pp. 867-871 ◽  
Author(s):  
M. Bes ◽  
S. Sauleda ◽  
I. Campos-Varela ◽  
F. Rodriguez-Frias ◽  
N. Casamitjana ◽  
...  

2004 ◽  
Vol 189 (7) ◽  
pp. 1140-1150 ◽  
Author(s):  
Sanaa M. Kamal ◽  
Camilla S. Graham ◽  
Qi He ◽  
Leonardo Bianchi ◽  
Ahmed A. Tawil ◽  
...  

2012 ◽  
Vol 209 (1) ◽  
pp. 61-75 ◽  
Author(s):  
Julian Schulze zur Wiesch ◽  
Donatella Ciuffreda ◽  
Lia Lewis-Ximenez ◽  
Victoria Kasprowicz ◽  
Brian E. Nolan ◽  
...  

Vigorous proliferative CD4+ T cell responses are the hallmark of spontaneous clearance of acute hepatitis C virus (HCV) infection, whereas comparable responses are absent in chronically evolving infection. Here, we comprehensively characterized the breadth, specificity, and quality of the HCV-specific CD4+ T cell response in 31 patients with acute HCV infection and varying clinical outcomes. We analyzed in vitro T cell expansion in the presence of interleukin-2, and ex vivo staining with HCV peptide-loaded MHC class II tetramers. Surprisingly, broadly directed HCV-specific CD4+ T cell responses were universally detectable at early stages of infection, regardless of the clinical outcome. However, persistent viremia was associated with early proliferative defects of the HCV-specific CD4+ T cells, followed by rapid deletion of the HCV-specific response. Only early initiation of antiviral therapy was able to preserve CD4+ T cell responses in acute, chronically evolving infection. Our results challenge the paradigm that HCV persistence is the result of a failure to prime HCV-specific CD4+ T cells. Instead, broadly directed HCV-specific CD4+ T cell responses are usually generated, but rapid exhaustion and deletion of these cells occurs in the majority of patients. The data further suggest a short window of opportunity to prevent the loss of CD4+ T cell responses through antiviral therapy.


2020 ◽  
Vol 4 (11) ◽  
pp. 701-712
Author(s):  
Nathália V. Batista ◽  
Yu-Han Chang ◽  
Kuan-Lun Chu ◽  
Kuan Chung Wang ◽  
Mélanie Girard ◽  
...  

2003 ◽  
Vol 72 (1) ◽  
pp. 66-74 ◽  
Author(s):  
Miguel A. Rico ◽  
Sara Ruiz ◽  
Dolores Subirá ◽  
Guillermina Barril ◽  
Secundino Cigarrán ◽  
...  

Hepatology ◽  
2015 ◽  
Vol 61 (4) ◽  
pp. 1163-1173 ◽  
Author(s):  
Guang Y. Li ◽  
Yun Zhou ◽  
Ruo S. Ying ◽  
Lei Shi ◽  
Yong Q. Cheng ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document